The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients.
Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient
D'AVOLIO, ANTONIO
;DE NICOLO', AMEDEO;
2017-01-01
Abstract
The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Taibi_et_al-2017-Journal_of_Clinical_Pharmacy_and_Therapeutics.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
336.69 kB
Formato
Adobe PDF
|
336.69 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
